当前位置: X-MOL 学术Mol. Genet. Genomics › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cost-efficiency tradeoff is optimized in various cancer types revealed by genome-wide analysis
Molecular Genetics and Genomics ( IF 3.1 ) Pub Date : 2021-01-15 , DOI: 10.1007/s00438-020-01747-w
Shufen Zhao , Shanai Song , Qi Qi , Wei Lei

The tradeoff between cost and efficiency is omnipresent in organisms. Specifically, how the evolutionary force shapes the tradeoff between biosynthetic cost and translation efficiency remains unclear. In the cancer community, whether the adjustment of cost-efficiency tradeoff acts as a strategy to facilitate tumor proliferation and contributes to oncogenesis is uninvestigated. To address this issue, we retrieved the gene expression profile in various cancer types and the matched normal samples from The Cancer Genome Atlas (TCGA). We found that the highly expressed genes in cancers generally have higher tAI/nitro ratios than those in normal samples. This is possibly caused by the higher tAI/nitro ratios observed in oncogenes than tumor suppressor genes (TSG). Furthermore, in the cancer samples, derived mutations in oncogenes usually lead to higher tAI/nitro ratios, while those mutations in TSG lead to lower tAI/nitro. For a special case of kidney cancer, we investigated several crucial genes in tumor samples versus normal samples, and discovered that the changes in tAI/nitro ratios are correlated with the changes in translation level. Our study for the first time revealed the optimization of cost-efficiency tradeoff in cancers. The cost-efficiency dilemma is optimized by the tumor cells, and is possibly beneficial for the translation and production of oncogenes, and eventually contributes to proliferation and oncogenesis. Our findings could provide novel perspectives in depicting the cancer genomes and might help unravel the cancer evolution.



中文翻译:

通过全基因组分析揭示了在各种癌症类型中的成本效率权衡得到了优化

成本与效率之间的权衡在有机体中无处不在。具体而言,尚不清楚进化力如何塑造生物合成成本与翻译效率之间的折衷。在癌症界,尚未研究成本效益折衷的调整是否作为促进肿瘤扩散并促进肿瘤发生的策略。为了解决这个问题,我们从癌症基因组图谱(TCGA)中检索了各种癌症类型和匹配的正常样品中的基因表达谱。我们发现癌症中高表达的基因通常比正常样品中的tAI /硝基比率更高。这可能是由于在癌基因中观察到的tAI /硝基比率高于肿瘤抑制基因(TSG)。此外,在癌症样本中 在癌基因中衍生的突变通常导致较高的tAI /硝基比,而在TSG中的那些突变导致较低的tAI /硝基比。对于肾癌的特殊情况,我们研究了肿瘤样品与正常样品中的几个关键基因,并发现tAI /硝基比的变化与翻译水平的变化相关。我们的研究首次揭示了癌症成本效率权衡的优化。成本效率困境由肿瘤细胞优化,可能有益于癌基因的翻译和生产,并最终促进增殖和致癌作用。我们的发现可能为描绘癌症基因组提供新颖的观点,并可能有助于阐明癌症的演变。对于肾癌的特殊情况,我们研究了肿瘤样品与正常样品中的几个关键基因,发现tAI /硝基比的变化与翻译水平的变化相关。我们的研究首次揭示了癌症成本效率权衡的优化。成本-效率困境由肿瘤细胞优化,可能对癌基因的翻译和生产有益,并最终促进增殖和致癌作用。我们的发现可能为描绘癌症基因组提供新颖的观点,并可能有助于阐明癌症的演变。对于肾癌的特殊情况,我们研究了肿瘤样品与正常样品中的几个关键基因,并发现tAI /硝基比的变化与翻译水平的变化相关。我们的研究首次揭示了癌症成本效率权衡的优化。成本-效率困境由肿瘤细胞优化,可能对癌基因的翻译和生产有益,并最终促进增殖和致癌作用。我们的发现可能为描绘癌症基因组提供新颖的观点,并可能有助于阐明癌症的演变。我们的研究首次揭示了癌症成本效率权衡的优化。成本效率困境由肿瘤细胞优化,可能有益于癌基因的翻译和生产,并最终促进增殖和致癌作用。我们的发现可能为描绘癌症基因组提供新颖的观点,并可能有助于阐明癌症的演变。我们的研究首次揭示了癌症成本效率权衡的优化。成本-效率困境由肿瘤细胞优化,可能对癌基因的翻译和生产有益,并最终促进增殖和致癌作用。我们的发现可能为描绘癌症基因组提供新颖的观点,并可能有助于阐明癌症的演变。

更新日期:2021-01-15
down
wechat
bug